At a glance
- Company
- Greenland Mines Ltd
- Ticker
- NASDAQ: GRML
Key figures
- Planned biotechnology division spin-off
- fourth quarter of 2026
- High-case pre-tax net present value for ST1
- approximately $2.05 billion
- Pre-tax internal rate of return for ST1
- 118.6%
- Estimated share of refining outside China
- approximately 34%
- Scheduled ST1 operating period
- nine
People
- Riad El-DadaStepping down from the board
- Dr. Shalom HirschmanStepping down from the board
- Jason HawkinsJoining the board
Products and programs

Greenland Mines (NASDAQ: GRML) announced a series of corporate milestones as it transitions into a focused rare earths and critical minerals company, including plans to spin off its biotechnology division in the fourth quarter of 2026. Nasdaq has formally approved the company application relating to its March 2026 transaction, resolving prior deficiencies and bringing Greenland Mines into full compliance with listing requirements. The company also completed its acquisition of the Sarfartoq project on Sept. 1 following approval by the Government of Greenland. An independent S-K 1300 Initial Assessment for the ST1 deposit estimated a high-case pre-tax net present value of approximately $2.05 billion and a pre-tax internal rate of return of 118.6%. Greenland Mines said planned annual neodymium-praseodymium oxide production from ST1 would equal approximately 34% of current NdPr oxide refining outside China based on 2025 consumption levels during each of the project nine scheduled operating years. The company is also reshaping its board, with Riad El-Dada and Dr. Shalom Hirschman stepping down and capital markets veteran Jason Hawkins joining as Greenland Mines advances Sarfartoq and its Skaergaard palladium-gold-platinum project.
To view the full press release, visit: https://ibn.fm/QN1U9
About Greenland Mines
Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: (1) Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and (2) Biotech, including Klotho’s KLTO‑202 primary indication for ALS. The Company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer
The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML
Corporate Communications
IBN
Austin, Texas
www.IBN.ai
512.354.7000 Office
[email protected]
In brief
Greenland Mines says it plans to separate its biotechnology division in the fourth quarter of 2026 as it concentrates on rare earths and other critical minerals. Nasdaq approved an application connected to a March 2026 transaction, which the company says addressed earlier listing deficiencies. Greenland Mines completed its purchase of the Sarfartoq project on Sept. 1 after receiving Greenland government approval. An independent assessment of the ST1 deposit put its high-case pre-tax net present value at about $2.05 billion and its pre-tax internal rate of return at 118.6%. The company estimates that planned ST1 output would represent about 34% of NdPr oxide refining outside China, using 2025 consumption levels, in each of nine operating years. It also announced board departures and the appointment of Jason Hawkins.
Key takeaways
- Greenland Mines plans to spin off its biotechnology division in Q4 2026.
- Nasdaq approved an application tied to a March 2026 transaction, resolving previously identified listing deficiencies, the company says.
- The company completed its Sarfartoq project acquisition on Sept. 1 after approval from the Government of Greenland.
- An ST1 assessment cited a high-case pre-tax NPV of about $2.05 billion and a 118.6% pre-tax IRR.
- Riad El-Dada and Dr. Shalom Hirschman are leaving the board; Jason Hawkins is joining.
SEC filings
- 8-KCURRENT REPORT Filed
- 8-KCURRENT REPORT Filed
- SCHEDULE 13GSCHEDULE 13G Filed
- 8-KCURRENT REPORT Filed
- 424B5PROSPECTUS SUPPLEMENT Filed
- 424B5PROSPECTUS SUPPLEMENTAL Filed
- 4PRIMARY DOCUMENT Filed
- 8-KCURRENT REPORT Filed
- 424B5PROSPECTUS SUPPLEMENT Filed
- 10-QQUARTERLY REPORT Filed
- 10-Q/AAMENDMENT NO. 1 TO FORM 10-Q/A Filed
- 10-K/AAMENDMENT NO. 1 TO FORM 10-K Filed
- NT 10-QNOTIFICATION OF LATE FILING Filed
- 8-KCURRENT REPORT Filed
Earlier from Greenland Mines
- Greenland Mines (NASDAQ: GRML) Highlights Sarfartoq Closing and Skaergaard Development Progress
- Greenland Mines (NASDAQ: GRML) Closes Sarfartoq Rare Earths Acquisition, Advances Project Toward Pre-Feasibility
- Greenland Mines (NASDAQ: GRML) Expects to Complete Sarfartoq Rare Earths Project Acquisition Before Sept. 1
- Greenland Mines (NASDAQ: GRML) Prices $20 Million Public Offering
- Greenland Mines (NASDAQ: GRML) Announces Proposed Public Offering to Fund Sarfartoq Acquisition